NASDAQ

After First Look at House Drug Plan, Stocks Rise Slightly

7 days ago   |   By Xconomy

The first details of the long-awaited House Democrat plan to lower drug prices leaked out Monday night, with elements that have long been anathema to the biopharma industry and its supporters in Washington. While the world digested the details Tuesday, however, biopharma investors didn't seem fazed. Some individual companies saw shares dip, but the biopharma indices of the Nasdaq and New York Stock Exchange were both up slightly at Tuesday's close. Full details of the proposal could come this week, according to the Washington Post. In current form the House bill “stands no chance of...
Read more ...

 


Search by Tags

   NASDAQ      Industrial      Biopharma      BioPharma      Drug      Drugs      Boston blog main      Boston top stories      Boulder      Denver blog main      Denver top stories      Detroit blog main      Detroit top stories      Indiana blog main      Indiana top stories      National      National blog main      National top stories      New York blog main      New York top stories      Raleigh-Durham blog main      Raleigh-Durham top stories      San Diego blog main      San Diego top stories      San Francisco blog main      San Francisco top stories      Seattle blog main      Seattle top stories      Texas blog main      Texas top stories      Wisconsin blog main      Wisconsin top stories      Bill &      Biotech      Democrats      Donald      Drug price      Federal      Fee      Fine      Government      HHS      House of Representatives      Index      Industry      Law      Life Sciences      Medicaid      Medicare      Nancy Pelosi      Negotiate      Negotiation      Plan      Pricing      Proposal      Secretary      Senate      Trump administration      Washington  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Why Menlo Ventures Backed Its First Construction Tech Firm

Why Menlo Ventures Backed Its First Construction Tech Firm

Fieldwire , whose mobile app helps builders and construction crews coordinate their work, announced today it has lined up a total of $33.5 million across two newly disclosed... Read more ...

HMS's $36M Deal to Buy VitreosHealth Combines Complementary Firms

HMS's $36M Deal to Buy VitreosHealth Combines Complementary Firms

One Texas-based healthcare software business has acquired another in an all-cash deal worth $36.5 million, the companies announced late Monday. Irving, TX-based HMS Holdings... Read more ...

ESnet a Key Partner on Project to Build Novel Network Research Infrastructure

ESnet a Key Partner on Project to Build Novel Network Research Infrastructure

Anticipated FABRIC topology at the end of construction. The National Science Foundation is funding a collaborative effort to create a nationwide research infrastructure that... Read more ...

Automated Trucking Company TuSimple Adds $120M More From Investors

Automated Trucking Company TuSimple Adds $120M More From Investors

UPS, the global package delivery giant, took a minority stake this summer in TuSimple, a self-driving trucking company, but didn't reveal financial details. On Tuesday, the San... Read more ...

Amplyx Inks Novartis Deal for Another Compromised-Immune System Drug

Amplyx Inks Novartis Deal for Another Compromised-Immune System Drug

Amplyx Pharmaceuticals, which is testing a new type of drug against life-threatening infections acquired by patients with compromised immune systems, has acquired the rights to... Read more ...

Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market

Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market

Denmark's neuroscience-focused pharma firm Lundbeck has agreed to pay $1.95 billion to acquire Seattle-based Alder BioPharmaceuticals to boost its late-stage pipeline and... Read more ...

KATRIN Cuts the Mass Estimate for the Elusive Neutrino in Half

KATRIN Cuts the Mass Estimate for the Elusive Neutrino in Half

A diagram of the layout and major features of the KATRIN experimental facility at the Karlsruhe Institute of Technology. (Credit: Karlsruhe Institute of Technology) Note: This... Read more ...

INmune Bio Invited to Speak on Company's Advancements in Cancer Treatments...

La Jolla, CA., Sept. 17, 2019 - INmune Bio, Inc. , an immunology company focused on developing treatments that harness the patient's innate immune system to fight disease... Read more ...

Equillium to Host Business Update Call on October 1, 2019

LA JOLLA, Calif., Sept. 17, 2019 - Equillium, Inc. , a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products to treat severe... Read more ...

AXIM® Biotechnologies Announces Cultivation Agreement to Establish Company's...

SAN DIEGO, Sept. 17, 2019 - AXIM® Biotechnologies, Inc. (“AXIM® Biotech,” “AXIM” or “the Company”) , a world leader in cannabinoid research and development, today announced... Read more ...